ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
-0,01%
Bitcoin
63.011,56
0,19%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Genmab AS (GMAB)

  7. Genmab AS (GMAB) News

GMAB Genmab AS

29,73
2,01 (7,25%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Genmab AS GMAB NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
2,01 7,25% 29,73 01:05:20
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
29,73 29,46 29,92 29,72 27,72
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202400:40BWFDA Grants Full Approval for TIVDAK® to Treat Recurrent or..
03.4.202407:35BWGenmab to Broaden and Strengthen Oncology Portfolio with..
11.3.202418:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.3.202419:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.3.202419:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.3.202423:04EDGAR2Form 144 - Report of proposed sale of securities
29.2.202417:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.2.202417:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27.2.202422:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27.2.202413:45BWU.S. FDA Accepts for Priority Review the Supplemental..
26.2.202418:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26.2.202416:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22.2.202422:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
20.2.202417:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.2.202421:42EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.2.202419:49EDGAR2Form 20-F - Annual and transition report of foreign private..
14.2.202418:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.2.202412:45BWTisotumab Vedotin Marketing Authorization Application..
31.1.202417:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23.1.202415:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.1.202413:45DJNPfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
09.1.202412:45BWTIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics..
03.1.202414:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.12.202317:46EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.12.202318:00BWNew Pivotal Data for Bispecific Antibody Epcoritamab..
01.12.202319:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27.11.202313:00BWGenmab Announces Positive Regulatory Updates for Epcoritamab..
21.11.202322:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.11.202316:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.11.202318:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.11.202317:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.11.202314:05BWGenmab Announces Multiple Abstracts to be Presented at the..
22.10.202316:30BWTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged..
17.10.202314:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.10.202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.9.202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25.9.202314:53EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25.9.202314:50DJNAbbVie, Genmab Get Conditional Europe OK of Tepkinly..
25.9.202313:45BWGenmab Announces European Commission Approval of TEPKINLY®..
25.9.202311:55BWEPKINLY™ (epcoritamab) Approved by Japan Ministry of Health,..
13.9.202315:59EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.9.202321:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.9.202315:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.9.202321:00BWSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv)..
16.8.202319:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15.8.202321:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03.8.202317:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.7.202315:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.7.202310:30BWGenmab Announces AbbVie Receives Positive CHMP Opinion for..
20.7.202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Kürzlich von Ihnen besucht

NASDAQ
GMAB
Genmab AS
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten